|
Name |
Cyclohexene, 3-(2-methylpropyl)-
|
Molecular Formula | C10H18 | |
IUPAC Name* |
3-(2-methylpropyl)cyclohexene
|
|
SMILES |
CC(C)CC1CCCC=C1
|
|
InChI |
InChI=1S/C10H18/c1-9(2)8-10-6-4-3-5-7-10/h4,6,9-10H,3,5,7-8H2,1-2H3
|
|
InChIKey |
NVLNRIBMCIJLQD-UHFFFAOYSA-N
|
|
Synonyms |
Cyclohexene, 3-isobutyl-; Cyclohexene, 3-(2-methylpropyl)-; 4104-56-7; 3-(2-Methylpropyl)-cyclohexene; 3-Isobutylcyclohexene-1; 3-Isobutyl-1-cyclohexene; 3-(2-Methylpropyl)-1-cyclohexene; 3-(2-Methylpropyl)cyclohex-1-ene; 3-isobutylcyclohex-1-ene; 3-(2-METHYLPROPYL)CYCLOHEXENE; CHEBI:88554; 3-(2-methyl-propyl)-cyclohexene; DTXSID00961400; Q27160445
|
|
CAS | 4104-56-7 | |
PubChem CID | 20057 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 138.25 | ALogp: | 4.1 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 10 | QED Weighted: | 0.503 |
Caco-2 Permeability: | -4.295 | MDCK Permeability: | 0.00002050 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.368 |
Blood-Brain-Barrier Penetration (BBB): | 0.692 | Plasma Protein Binding (PPB): | 95.68% |
Volume Distribution (VD): | 3.204 | Fu: | 4.30% |
CYP1A2-inhibitor: | 0.931 | CYP1A2-substrate: | 0.768 |
CYP2C19-inhibitor: | 0.59 | CYP2C19-substrate: | 0.815 |
CYP2C9-inhibitor: | 0.559 | CYP2C9-substrate: | 0.886 |
CYP2D6-inhibitor: | 0.07 | CYP2D6-substrate: | 0.38 |
CYP3A4-inhibitor: | 0.504 | CYP3A4-substrate: | 0.215 |
Clearance (CL): | 10.848 | Half-life (T1/2): | 0.26 |
hERG Blockers: | 0.006 | Human Hepatotoxicity (H-HT): | 0.017 |
Drug-inuced Liver Injury (DILI): | 0.041 | AMES Toxicity: | 0.011 |
Rat Oral Acute Toxicity: | 0.029 | Maximum Recommended Daily Dose: | 0.021 |
Skin Sensitization: | 0.496 | Carcinogencity: | 0.153 |
Eye Corrosion: | 0.976 | Eye Irritation: | 0.99 |
Respiratory Toxicity: | 0.097 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000492 | 0.366 | D03DVJ | 0.255 | ||||
ENC000383 | 0.279 | D04CSZ | 0.213 | ||||
ENC005848 | 0.278 | D08KVZ | 0.197 | ||||
ENC005708 | 0.278 | D09PJX | 0.195 | ||||
ENC005974 | 0.278 | D0I0EG | 0.182 | ||||
ENC001907 | 0.278 | D0P4MT | 0.169 | ||||
ENC000834 | 0.278 | D08MRN | 0.169 | ||||
ENC002264 | 0.267 | D0W1QI | 0.169 | ||||
ENC000872 | 0.267 | D05QIM | 0.167 | ||||
ENC003835 | 0.246 | D06PSS | 0.165 |